Stay updated on Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.

Latest updates to the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now shows a 'Last Update Posted (Estimated)' field and a 'Revision: v3.3.2' label, while the previous 'Last Update Posted' and 'Revision: v3.3.1' labels were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoChange DetectedLocation information updated: the study now lists 86 locations and several sites were removed (Dnipro, Madrid, Porto, Loures, Lisbon). A PubMed-derived publications note and a new revision (v3.3.1) were also added.SummaryDifference0.5%

- Check24 days agoChange DetectedRemoved a site-wide notice about government funding lapses, which does not affect the trial's core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check38 days agoChange DetectedThe updates appear to be cosmetic, with only formatting/layout adjustments to the Study Details page and no changes to core trial content such as design, eligibility criteria, interventions, primary/secondary outcomes, or listed sites. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check68 days agoChange DetectedUpdate: revision number upgraded from v3.0.2 to v3.2.0, indicating a new release. No other content changes detected.SummaryDifference0.1%

- Check69 days agoChange DetectedUpgrade of the page version from v3.0.2 to v3.1.0; a metadata/versioning change with no impact on core content or user-facing data.SummaryDifference0.1%

Stay in the know with updates to Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral vs Injectable Fulvestrant in Breast Cancer Clinical Trial page.